Evidence map›Paper›PMID 41727234›Full record

ArticlePeerJ2026

Probiotic-infused activated charcoal/ hydroxyapatite microbeads: a novel strategy to disinfection.

Mohammed A Alqumber

Abstract read
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mohammed A AlqumberLaboratory Medicine Department, Faculty of Applied Medical Sciences, Alaqiq, Al-Baha, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To develop a non-toxic, probiotic-infused activated charcoal/hydroxyapatite microbeads (PIMD) formulated with activated charcoal and hydroxyapatite. The formulation is designed to establish a stable probiotic biofilm on high-risk surfaces, such as medical sink basins and food cutting boards. Its dual mechanism aims to achieve rapid pathogen inhibition and long-term protection through sustained competitive exclusion, including against antibiotic-resistant microorganisms. Methods: An applied study was conducted in the Al-Baha region of Saudi Arabia (January 2021-May 2025) employing probiotic-based biotechnology to engineer spatially segregated microenvironments using activated charcoal-hydroxyapatite microbeads. The study integrated ecological modeling concepts-including Gause's competitive exclusion principle, Lotka-Volterra dynamics and agent-based cross-feeding simulations-with antimicrobial sensitivity assays and surface disinfection trials. Twelve probiotic strains capable of competitively excluding pathogens and producing antimicrobial compounds were encapsulated within activated charcoal and hydroxyapatite porous microbeads. The efficacy of the novel disinfectant was evaluated on stainless steel sink basins, food-grade cutting boards, and culture plates challenged with 43 pathogenic strains. Results: The PIMD formulation remained physically stable under storage conditions, with probiotic viability largely preserved at -20 °C (0.46 log Conclusion: PIMD represents a dual-action strategy combining rapid disinfection with sustainable microbial balance, for reducing reliance on antibiotics and chemical disinfectants while enhancing surface safety in diverse environments such as healthcare, food facilities, and beyond.

Indexed as

CharcoalDisinfectionDurapatiteMicrospheresProbioticsBiofilmsDisinfectantsCharcoalDisinfectantsDurapatiteActivated charcoal microbeadsAntimicrobial biofilmCompetitive exclusionEcological disinfectionHydroxyapatite microbeadsPathogen suppressionProbiotic disinfectantSurface decontaminationSustainable disinfection

Identifiers

PMID41727234
PMCPMC12924655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.